Netherlands

Orbis Medicines secures €90M to advance Oral Macrocycle Drug Discovery
Orbis Medicines, a cutting-edge drug discovery company headquartered in Copenhagen, has raised €90 million in a Series A funding round, bringing its total funding to €116 million.